Sanofi’s multiple sclerosis candidate tolebrutinib is in line for a potential US approval in the autumn after the Food and Drug Administration agreed to a speedy review of the oral Bruton’s tyrosine kinase (BTK) inhibitor.
Sanofi Nabs Priority Review For MS Drug Tolebrutinib
A decision from the FDA is due by 28 September.
